Intellia Therapeutics (NTLA) AI Stock Analysis

• Market Cap: $1.07B
• Dividend Yield: N/A
• Average Volume (3M): 5.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.23
• Revenue Growth: 33.52%
• EPS Growth: 21.66%
• Country: US
• Employees: 403
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.92
• Shares Outstanding: 115,829,926
• 10 Day Avg. Volume: 3,295,636
• 30 Day Avg. Volume: 5,501,753
• PEG Ratio: 0.71
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 19.91
• P/FCF Ratio: -3.25
• Enterprise Value/Market Cap: 1.39
• Enterprise Value/Revenue: 25.90
• Enterprise Value/Gross Profit: -69.55
• Enterprise Value/Ebitda: -3.27
• 1Y Price Target: $16.62
• Price Target Upside: 80.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 22
• EPS Forecast (FY): -4
• Revenue Forecast (FY): $56.49M

• Rating: 47 Neutral
• Price Target: $9.50 ▲(2.93% Upside)

Intellia Therapeutics' overall stock score reflects the significant challenges it faces in its financial performance and valuation, typical of a biotech firm in its growth phase. The technical analysis provides a neutral outlook, while the earnings call highlights both progress and significant setbacks, particularly the clinical hold on key trials. The company's strong cash position offers some stability, but the risks associated with its clinical trials and financial losses weigh heavily on its score.

Positive Factors

Strong Cash Position

A strong cash position provides financial stability and flexibility, allowing Intellia to continue investing in R&D and manage operational costs while advancing its clinical programs.

Positive Clinical Trial Data

Positive clinical trial results for lonvo-z suggest potential for successful treatment options, enhancing Intellia's competitive position in gene editing therapies and supporting future revenue growth.

Collaboration Revenue Growth

Increased collaboration revenue indicates successful partnerships, enhancing financial resources and supporting ongoing R&D efforts, which are crucial for long-term growth and innovation.

Negative Factors

Clinical Hold on Trials

The clinical hold on key trials due to safety concerns poses a significant risk to Intellia's pipeline progress and potential revenue, impacting its ability to bring new therapies to market.

Declining Revenue

A decline in revenue reflects challenges in monetizing research and development efforts, potentially affecting Intellia's financial sustainability and ability to fund future projects.

High Net Losses

High net losses highlight the financial strain of ongoing R&D expenses without offsetting revenue, which can limit Intellia's operational flexibility and long-term viability.

Intellia Therapeutics Business Overview & Revenue Model

Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Intellia Therapeutics generates revenue through a combination of research collaborations, licensing agreements, and potential future product sales. The company often partners with larger pharmaceutical firms, which provide upfront payments and milestone payments tied to the achievement of specific development goals. Additionally, Intellia may receive royalties on the sales of any products developed through these collaborations. As the company advances its clinical programs and moves closer to commercialization, it may also begin to realize revenue from product sales once its therapies receive regulatory approvals. Key partnerships with organizations such as Regeneron Pharmaceuticals enhance its research capabilities and financial resources, contributing significantly to its earnings potential.

Intellia Therapeutics Financial Statement Overview

Summary

Intellia Therapeutics is experiencing typical financial challenges for a biotech firm in its growth phase, with high R&D expenses leading to net losses and negative cash flows. The balance sheet shows adequate cash reserves, but declining shareholder equity and zero revenue in 2024 highlight significant risks in future revenue generation and profitability.

Income Statement

Intellia Therapeutics has faced a challenging financial environment, with declining revenues from $57.99 million in 2020 to $36.27 million in 2023, and ultimately to zero in 2024. The company has consistently incurred net losses, with a significant net loss of $519.02 million in 2024, indicating high operational costs and low revenue, characteristic of a biotech firm in early stages of development.

Balance Sheet

The balance sheet shows adequate cash reserves with $601.52 million in cash and equivalents. However, the debt-to-equity ratio stands at 0.24, indicating manageable leverage, but the persistent decrease in stockholders' equity from $1.05 billion in 2023 to $871.96 million in 2024 suggests a deterioration in shareholder value. The equity ratio is relatively stable, providing a moderate level of financial stability.

Cash Flow

The cash flow statement highlights negative free cash flow each year, with a free cash flow of -$408.07 million in 2024, driven by high operating cash outflows. The operating cash flow to net income ratio is unfavorable due to consistent losses, signaling inefficiencies in cash generation relative to expenses. This is typical for a biotech firm still in development phases.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	57.53M	57.88M	36.27M	52.12M	33.05M	57.99M
Gross Profit	-21.42M	47.59M	27.30M	44.55M	26.16M	-92.41M
EBITDA	-456.10M	-523.98M	-506.31M	-450.59M	-260.96M	-130.27M
Net Income	-445.81M	-519.02M	-481.19M	-474.19M	-267.89M	-134.23M
Balance Sheet
Total Assets	925.27M	1.19B	1.30B	1.52B	1.29B	676.32M
Cash, Cash Equivalents and Short-Term Investments	511.04M	601.51M	912.22M	1.19B	748.69M	597.37M
Total Debt	97.97M	210.20M	115.35M	130.70M	74.02M	39.30M
Total Liabilities	176.85M	319.06M	250.81M	284.53M	254.22M	149.25M
Stockholders Equity	748.42M	871.96M	1.05B	1.24B	1.04B	527.07M
Cash Flow
Free Cash Flow	-412.63M	-354.66M	-408.07M	-391.68M	-237.79M	-53.50M
Operating Cash Flow	-410.65M	-348.88M	-394.09M	-333.29M	-225.03M	-49.91M
Investing Cash Flow	352.06M	125.57M	-31.35M	160.31M	-550.78M	-214.49M
Financing Cash Flow	131.83M	185.75M	130.32M	582.96M	736.69M	371.78M

Intellia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Neutral. The current price of 9.23 is above the 20-day moving average (MA) of 8.97, below the 50-day MA of 13.31, and below the 200-day MA of 11.33, indicating a neutral trend. The MACD of -0.74 indicates Negative momentum. The RSI at 43.35 is Neutral, neither overbought nor oversold. The STOCH value of 21.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NTLA.

Intellia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$887.53M	-10.90	-37.82%	―	-100.00%	-28.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABCL	49 Neutral	$1.08B	-6.25	-16.81%	―	7.16%	3.95%
BCAX	48 Neutral	$964.16M	-7.89	-26.64%	―	―	-103.95%
NTLA	47 Neutral	$1.07B	-2.16	-52.11%	―	33.52%	21.66%
KURA	47 Neutral	$856.25M	-3.97	-65.10%	―	―	-5.18%
JANX	45 Neutral	$829.44M	-8.23	-12.48%	―	-23.37%	-42.45%

Intellia Therapeutics Corporate Events

Intellia Reports Favorable Phase 1 Data for Nex-Z

On November 8, 2025, Intellia Therapeutics announced positive results from its Phase 1/2 trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, showing significant reductions in plasma kallikrein and a favorable safety profile. The trial results, presented at a scientific meeting, suggest lonvo-z could become a one-time treatment option, with a Phase 3 trial ongoing. On November 10, 2025, Intellia also reported favorable Phase 1 data for nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with cardiomyopathy, demonstrating sustained serum TTR reduction and disease stabilization. However, the FDA placed a clinical hold on the Phase 3 trials for nex-z, impacting its development timeline.

Intellia Therapeutics Faces FDA Clinical Hold on Trials

On October 29, 2025, Intellia Therapeutics was informed by the FDA of a clinical hold on their Phase 3 trials for nexiguran ziclumeran due to safety concerns. The hold follows reports of severe liver issues in a patient, prompting the company to pause the trials and work with the FDA to resolve the matter.

Intellia Therapeutics Pauses Phase 3 Trials Due to Safety Concerns

On October 27, 2025, Intellia Therapeutics announced a temporary pause in dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran (nex-z) due to a report of severe liver issues in a patient. This decision affects trials for transthyretin amyloidosis with cardiomyopathy and polyneuropathy, involving over 650 and 47 patients respectively. The company is consulting with experts and regulatory authorities to address the safety concerns and strategize resuming the trials, highlighting its commitment to patient safety and regulatory compliance.

Intellia Therapeutics Announces Positive Phase 1 Trial Results

On September 25, 2025, Intellia Therapeutics announced positive longer-term data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy. The trial showed deep, durable TTR reductions and favorable safety data, with most patients experiencing stability or improvement in clinical measures. The company is advancing its Phase 3 MAGNITUDE-2 trial, with completion of enrollment expected in the first half of 2026, and plans to submit a biologics license application by 2028.